From Epithelium to Therapy: Transitional Cells in Lung Fibrosis
American Journal of Respiratory Cell and Molecular Biology · 01.05.2025 · 72 (5) · 472-483
DOI: 10.1165/rcmb.2024-0372tr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.05.2025. Verfasst von Sarah Y Shin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Patients with idiopathic pulmonary fibrosis and lung fibrosis secondary to infections such as influenza A and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have limited treatment options outside of supportive therapy and lung transplantation. Multiple lung stem cell populations have been implicated in the pathogenesis of lung fibrosis, and more progenitor cell populations continue to be discovered and characterized. In this review, we summarize the functions and differentiation pathways of various cells that constitute the lung epithelium. We then focus on two subpopulations of KRT5+ or KRT8+ transitional cells that both originate from alveolar type II cells but experience different cell fates and play important roles in lung regeneration and repair. We address these transitional cells’ potential role in fibrosis and bronchiolization of the alveoli, as they are correlated to aggregate near fibrotic foci in both in vivo models and in human fibrotic lung disease. We conclude by discussing recent advances in cell and organoid therapy to replace aberrant transitional cells and treat lung fibrosis. Namely, we focus on strategies to minimize immune clearance of transplanted cells and to optimize engraftment by transplanting cells precultured as three-dimensional organoids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and.
- Department of Diagnostic and Biomedical Sciences, School of Dentistry, UTHealth Houston, Houston, Texas.
- Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, Ohio.
- Department of Stem Cell Transplantation and Cell Therapy, MD Anderson Cancer Center, Houston, Texas.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, McGovern Medical School, Houston, Texas.
- Center for Advanced Cardiopulmonary Therapies and Transplantation, University of Texas Health Science Center at Houston, Houston, Texas.
ORCID-Profile: Sarah Y Shin, Harry Karmouty-Quintana
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Shin, S. Y., Chen, J., Milman Krentsis, I., Reisner, Y., Abrencillo, R., Hussain, R., Wu, D., & Karmouty-Quintana, H. (2025). From Epithelium to Therapy: Transitional Cells in Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 72(5), 472-483. https://doi.org/10.1165/rcmb.2024-0372tr
Vancouver
Shin SY, Chen J, Milman Krentsis I, Reisner Y, Abrencillo R, Hussain R, et al. From Epithelium to Therapy: Transitional Cells in Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 2025;72(5):472-483. doi:10.1165/rcmb.2024-0372tr
BibTeX
@article{Shin2025,
author = {Shin, Sarah Y and Chen, Jichao and Milman Krentsis, Irit and Reisner, Yair and Abrencillo, Rodeo and Hussain, Rahat and Wu, Danielle and Karmouty-Quintana, Harry},
title = {From Epithelium to Therapy: Transitional Cells in Lung Fibrosis},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
volume = {72},
number = {5},
pages = {472--483},
doi = {10.1165/rcmb.2024-0372tr}
}
EUVIMED